Description
Background:
Mirzotamab is an IgG1 antibody targeting to CD276/B7-H3. Mirzotamab can conjugates with Clezutoclaxum, an BCL2L1 inhibitor to form Mirzotamab clezutoclax , involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax is a targeted antibody drug conjugate (ADC).
Intended Use:
For Estimation of Mirzotamab in human serum and plasma. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us at sales@krishgen.com for optimization.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!